Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers.

Johnson, Franklin K; Mudd, Paul N; Bragat, Alexander; Adera, Mathews; Boudes, Pol

Johnson, Franklin K; Mudd, Paul N; Bragat, Alexander; Adera, Mathews; Boudes, Pol.

Afiliação

Johnson FK; Clinical Pharmacology, Amicus Therapeutics, Cranbury, NJ, USA.
Mudd PN; Clinical Pharmacology, GlaxoSmithKline, Research Triangle Park, NC, USA.
Bragat A; Clinical Development, Amicus Therapeutics, Cranbury, NJ, USA.
Adera M; Clinical Development, Amicus Therapeutics, Cranbury, NJ, USA.
Boudes P; Clinical Development, Amicus Therapeutics, Cranbury, NJ, USA.

Clin Pharmacol Drug Dev ; 2(2): 120-32, 2013 Apr.

Article em En | MEDLINE | ID: mdl-27121667

Palavras-chave

Fabry disease; enzyme replacement therapy; lysosomal storage disorders; pharmacokinetics; pharmacological chaperone

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: Clin Pharmacol Drug Dev Ano de publicação: 2013 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google